Vitamin B2 (riboflavin): the mirage of safety

B2: the electron shuttle of cellular life

Riboflavin is the precursor of two fundamental coenzymes: FMN (flavin mononucleotide) and FAD (flavin adenine dinucleotide). These two molecules participate in dozens of oxidation-reduction reactions in the mitochondria, the respiratory chain, the synthesis of steroid hormones, iron mobilisation, and the folate cycle.¹²

Imagine it this way: a cellular assembly line where workers must constantly deposit and collect loads (electrons) from one station to another. B2 is this universal shuttle worker. If it is missing from its post, the entire production line slows — without any specific alarm going off, because each station adapts as best it can. This is precisely what makes subclinical B2 deficiency so difficult to spot.³

A century of ignored warnings

Riboflavin was isolated in 1926–1933 (independently by Warburg, Kuhn, and several teams), and ariboflavinosis — the clinical form of deficiency — was already well described in the 1940s in rural populations of Asia, Africa, and Central America.⁴

After flour fortification in the 1950s–60s, Western health authorities classified the problem as “solved.” Yet surveys in the following decades continued to document a persistent prevalence of subclinical deficiency among adolescent girls, the elderly, and vegetarians — data largely ignored.⁵

In 2020, a major review in the International Journal of Molecular Sciences concluded:

“Insufficient dietary intake of riboflavin is often reported in nutritional surveys and population studies, even in non-developing countries with abundant sources of riboflavin-rich dietary products.”⁵¹

In 2023, the Annual Review of Nutrition stated:

“Subclinical deficiency may be much more widespread, including in high-income countries, but typically goes undetected because riboflavin biomarkers are rarely measured in human studies.”³

The pattern is well known: scientific finding, institutional forgetting, rediscovery — and in between, generations of undiagnosed patients.

B2 is not “easy to obtain”

The standard discourse is that B2 is abundantly found in dairy products, meat, eggs, and fortified cereals. Technically true — but several structural features of modern diets work against it:

• Extreme photosensitivity: milk exposed to light (transparent bottles, supermarket shelves) loses a significant fraction of its B2 content¹
• Prolonged cooking: degrades riboflavin, particularly in boiled vegetables
• Declining consumption of dairy products and offal (organs extremely rich in B2) in modern habits, particularly among adolescent girls
• Vegan diets without specific attention to B2: structurally poor
• Alcohol: reduces intestinal absorption
• Oral contraceptives and certain antidepressants (tricyclics, phenothiazines): alter riboflavin metabolism⁶
• Intense physical exercise: significantly increases B2 requirements (muscle oxidation-reduction reactions)⁶

Deficiency in numbers: beyond the developing world

The real data, where they have been measured, are alarming.

• United Kingdom: 59% of boys aged 2–6 and 78% of boys aged 7–10 had insufficient B2 status; 95% of girls aged 15–18 had insufficient intake⁷
• Europe: 7 to 20% of adults deficient, up to 27% in the United States⁷
• Italy: approximately 20% of the elderly with subclinical deficiency⁸
• Canada (young women): only 7% had intakes below the recommended threshold — but 40% had biochemical deficiency measured by EGRAC ≥ 1.40, despite apparently adequate dietary intakes⁹

That last figure is particularly revealing: it shows the gap between measured dietary intake and real biochemical status — theoretical intakes do not predict actual cellular utilization.

“Subclinical deficiency may be much more widespread, including in high-income countries, but typically goes undetected because riboflavin biomarkers are rarely measured in human studies. There are adverse health consequences of low and deficient riboflavin status throughout the life cycle, including anemia and hypertension, that could contribute substantially to the global burden of disease.” — Annual Review of Nutrition, 2023³

Polymorphisms: B2 and the MTHFR bomb

The transporters (SLC52A1, SLC52A2, SLC52A3)

Three genes encode riboflavin transporters (RFVT1, RFVT2, RFVT3):¹⁰

• SLC52A3 (RFVT3): expressed on the intestinal surface, responsible for dietary B2 absorption
• SLC52A2 (RFVT2): expressed in the brain and nervous system, responsible for intracerebral transport
• SLC52A1 (RFVT1): involved in placental transport

Loss-of-function mutations in SLC52A2 and SLC52A3 cause RTD (Riboflavin Transporter Deficiency) — formerly known as Brown-Vialetto-Van Laere and Fazio-Londe syndromes — a progressive neurodegenerative disease. Crucially: blood B2 levels may appear normal even when nerve cells are deprived of riboflavin, because the defective transporter blocks intracellular entry.¹¹¹⁰

“When a variant occurs in any of these three [transporter] genes, the resulting transporter protein may be abnormal, inefficient or entirely absent. This defect prevents riboflavin from crossing cell membranes, so even if blood levels of vitamin B2 appear normal, cells become starved of this vital nutrient.” — NORD (National Organization for Rare Disorders)¹⁰

The MTHFR 677C>T polymorphism: a major risk multiplier

The MTHFR 677C>T polymorphism affects 30 to 60% of the population depending on ethnicity — making it one of the most clinically relevant genetic interactions linked to B2.

The MTHFR enzyme (methylenetetrahydrofolate reductase) is riboflavin-dependent: it needs FAD (derived from B2) as a cofactor to function. The 677C>T variant modifies the enzyme’s structure, reducing its affinity for FAD. Result: in carriers (heterozygous CT or homozygous TT), the MTHFR enzyme functions poorly — particularly when riboflavin status is low.¹²¹³¹⁴

The consequences are serious:

• Accumulation of homocysteine (cardiovascular, thrombotic, and neurotoxic risk factor)¹⁵¹²
• Methylation defect (insufficient production of 5-methyltetrahydrofolate → neurotransmitters, DNA repair, detoxification)
• Riboflavin supplementation (1.6 mg/day) reduces homocysteine by 22 to 40% in TT genotype carriers with low B2 status¹²
• In these individuals, folate supplementation alone is insufficient — without adequate B2, the enzyme remains defective regardless of the folate dose¹³

“MTHFR is therefore a riboflavin-dependent enzyme, and the less riboflavin available, the less functional it becomes. People with the MTHFR 677CT mutation had high homocysteine levels only if they had low riboflavin levels.”¹²

In practice, millions of people carrying the MTHFR polymorphism and taking methylated folate supplements are not getting the expected results — simply because their underlying B2 deficiency has not been identified and corrected.

Frequent diagnostic confusions

Chronic migraine: the neuronal mitochondria is hyperactivated during an attack. B2 is a cofactor of complexes I and II of the mitochondrial respiratory chain, and underlying mitochondrial defects have been documented in migraineurs. Several clinical trials show that 400 mg/day of riboflavin reduces migraine frequency by half within 3 months in responsive patients.¹⁶²

“Unexplained” anaemia: B2 is necessary for iron mobilisation and erythropoietin production; deficiency can cause a normocytic or microcytic anaemia that does not respond to iron, mimicking refractory iron-deficiency anaemia.²

Thyroid and adrenal glands: B2 regulates the synthesis of thyroid and adrenal hormones; deficiency increases the risk of thyroid disease, and symptoms of dysthyroidism may in fact reflect riboflavin deficiency.²

Cardiovascular disease and hypertension: via homocysteine accumulation in MTHFR carriers, riboflavin deficiency directly increases cardiovascular risk — a documented mechanism rarely mentioned in clinical consultations.¹⁷

Other frequent confusions: cataracts and glaucoma, peripheral neuropathies (often attributed to diabetes or B12 without measuring B2), chronic fatigue, and depression.

Tests: the same limitations as other B vitamins

Plasma riboflavin: reliable only in the short term

Standard laboratory measurement reflects intakes from the preceding 48–72 hours, not tissue stores. A meal rich in dairy products before the blood draw can artificially normalize results.¹⁸

EGRAC — the reference functional test

EGRAC (erythrocyte glutathione reductase activation coefficient) is the functional equivalent of the ETKAC test for other B vitamins. Its important limitations:¹⁹²⁰

• Unusable in people with G6PD deficiency (common in some African, Mediterranean, and Asian populations) — this deficiency artificially increases the enzyme’s affinity for FAD, giving a falsely normal result
• Lack of international standardization of thresholds (IOM considers EGRAC <1.2 as acceptable, 1.2–1.4 as low, >1.4 as deficient — but these thresholds are contested)
• In RTD cases, cells can be starved of B2 with a normal EGRAC because the defect lies downstream of transport, not in the circulating quantity¹⁰

Health authorities vs scientific reality

The NIH fact sheet (updated March 2026) considers frank deficiency rare in developed countries and recommends 1.1–1.3 mg/day. StatPearls (NIH) describes deficiency as a “rare condition” in well-nourished societies.²¹⁴

Yet:

• The Canadian survey shows 40% biochemical deficiency among young women with theoretically adequate intakes⁹
• The Annual Review of Nutrition 2023 emphasizes that biomarkers are rarely measured, making official statistics not reassuring but meaningless³
• The official NIH fact sheet does not mention the central role of B2 in MTHFR functionality, despite documentation going back to the 2000s¹⁴

The paradox is clear: recommendations are formulated in mg/day as if absorption, enzymatic utilization, dietary photosensitivity, and genetic variability did not exist.

Researchers who have sounded the alarm

Unlike some other nutrients, B2 does not yet have a major public-facing figure. The most active academic researchers include:

• Prof Helene McNulty (Ulster University, Northern Ireland): world specialist in the riboflavin–MTHFR–blood pressure interaction; author of several key studies on B2 supplementation in MTHFR carriers²²
• Prof Kathleen Sheridan & Dr Anne Molloy (Trinity College Dublin): work on B2, folate, homocysteine, and methylation¹²
• Team of Lena Brundin (Sweden): work on RTD and neuroprotection with high-dose riboflavin¹¹
• HormonesMatter.com (Chandler Marrs): also publishes articles on B2 in relation to mitochondrial cofactors

The hope: simple, safe, and potentially transformative

Riboflavin combines three rare properties: high safety (even at elevated doses), very low cost, and the potential for reversibility of sometimes debilitating symptoms. The bright yellow urine observed at high doses is a benign sign.⁴

For carriers of the MTHFR 677 TT polymorphism, correcting low B2 status can:

• Normalise homocysteine without high-dose methylfolate
• Reduce the cardiovascular risk associated with the polymorphism
• Improve overall methylation (mood, cognition, detoxification)

For migraineurs with mitochondrial dysfunction, 400 mg/day of riboflavin has an efficacy profile comparable to prophylactic medications — with zero serious side effects.¹⁶

For people unknowingly carrying an MTHFR variant, or simply following a modern diet poor in dairy products and offal, 1.6 to 3 mg/day of riboflavin can represent a significant metabolic shift.

“A latent subclinical riboflavin deficiency can result in a significant clinical phenotype when combined with inborn genetic disturbances or environmental and physiological factors like infections, exercise, diet, aging and pregnancy.” — International Journal of Molecular Sciences, 2020¹

Within the framework of the Right to Physiological Integrity, this grounds a right to an optimal riboflavin status: the right to recognition of subclinical deficiency, to relevant tests including EGRAC, and to safe, low-cost supplementation strategies to correct a deficit that, today, hides in plain sight.

References